肠道菌群失调在慢加急性肝衰竭中的作用
The Role of Gut Dysbiosis in Acute-on-Chronic Liver Failure.
机构信息
Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24252, Korea.
Institute for Liver and Digestive Diseases, Hallym University, Chuncheon 24252, Korea.
出版信息
Int J Mol Sci. 2021 Oct 28;22(21):11680. doi: 10.3390/ijms222111680.
Abstract
Acute-on-chronic liver failure (ACLF) is an important syndrome of liver failure that has a high risk of short-term mortality in patients with chronic liver disease. The development of ACLF is associated with proinflammatory precipitating events, such as infection, alcoholic hepatitis, and intense systemic inflammation. Recently, the role of the gut microbiome has increasingly emerged in human health and disease. Additionally, the gut microbiome might have a major role in the development of liver disease. In this review, we examine evidence to support the role of gut dysbiosis in cirrhosis and ACLF. Additionally, we explore the mechanism by which the gut microbiome contributes to the development of ACLF, with a focus on alcohol-induced liver disease.
摘要
急性慢性肝衰竭（ACLF）是一种重要的肝衰竭综合征，患有慢性肝病的患者具有很高的短期死亡率风险。ACLF 的发展与促炎诱发事件有关，例如感染、酒精性肝炎和强烈的全身炎症。最近，肠道微生物组在人类健康和疾病中的作用日益凸显。此外，肠道微生物组可能在肝病的发展中起主要作用。在这篇综述中，我们研究了支持肠道菌群失调在肝硬化和 ACLF 中的作用的证据。此外，我们还探讨了肠道微生物组如何促进 ACLF 的发展，重点关注酒精性肝病。
相似文献
1
The Role of Gut Dysbiosis in Acute-on-Chronic Liver Failure.肠道菌群失调在慢加急性肝衰竭中的作用
Int J Mol Sci. 2021 Oct 28;22(21):11680. doi: 10.3390/ijms222111680.
2
The microbiota in cirrhosis and its role in hepatic decompensation.肝硬化中的微生物群及其在肝性失代偿中的作用。
J Hepatol. 2021 Jul;75 Suppl 1(Suppl 1):S67-S81. doi: 10.1016/j.jhep.2020.11.013.
3
Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.利用肠道微生物组治疗肝硬化失代偿期和慢加急性肝衰竭。
Nat Rev Gastroenterol Hepatol. 2021 Mar;18(3):167-180. doi: 10.1038/s41575-020-00376-3. Epub 2020 Nov 30.
4
Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis.入院时肠道微生物群与肝硬化患者结局的关系。
Clin Gastroenterol Hepatol. 2019 Mar;17(4):756-765.e3. doi: 10.1016/j.cgh.2018.07.022. Epub 2018 Jul 20.
5
Altered Microbiome in Patients With Cirrhosis and Complications.肝硬化及并发症患者的肠道微生物组改变。
Clin Gastroenterol Hepatol. 2019 Jan;17(2):307-321. doi: 10.1016/j.cgh.2018.08.008. Epub 2018 Aug 9.
6
Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality.慢性肝衰竭急性发作中的肠道菌群失调及其对死亡率的预测价值。
J Gastroenterol Hepatol. 2015 Sep;30(9):1429-37. doi: 10.1111/jgh.12932.
7
Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.综述文章：肠道微生物组作为慢性肝病发病机制和治疗的治疗靶点。
Aliment Pharmacol Ther. 2018 Jan;47(2):192-202. doi: 10.1111/apt.14397. Epub 2017 Oct 30.
8
Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis.通过定量宏基因组学评估肝硬化患者肠道微生物群的改变：与慢加急性肝衰竭及预后的关系
Gastroenterology. 2021 Jan;160(1):206-218.e13. doi: 10.1053/j.gastro.2020.08.054. Epub 2020 Sep 14.
9
Disruption of the gut-liver axis in the pathogenesis of acute-on-chronic liver failure.肠道-肝脏轴在慢加急性肝衰竭发病机制中的破坏
Eur J Gastroenterol Hepatol. 2018 Feb;30(2):130-135. doi: 10.1097/MEG.0000000000001026.
10
Liver cirrhosis and immune dysfunction.肝硬化和免疫功能障碍。
Int Immunol. 2022 Sep 6;34(9):455-466. doi: 10.1093/intimm/dxac030.
引用本文的文献
1
The role of bacterial outer membrane vesicles in inflammatory response of acute-on-chronic liver failure.细菌外膜囊泡在慢加急性肝衰竭炎症反应中的作用
Front Microbiol. 2025 Jul 4;16:1608137. doi: 10.3389/fmicb.2025.1608137. eCollection 2025.
2
Panose prevents acute-on-chronic liver failure by reducing bacterial infection in mice.帕拉米韦通过减少小鼠细菌感染来预防慢性肝衰竭急性发作。
J Clin Invest. 2025 Jun 3;135(14). doi: 10.1172/JCI184653. eCollection 2025 Jul 15.
3
3PM-guided innovation in treatments of severe alcohol-associated hepatitis utilizing fecal microbiota transplantation.利用粪便微生物群移植在严重酒精性肝炎治疗中进行以精准医学为导向的创新。
EPMA J. 2024 Oct 31;15(4):677-692. doi: 10.1007/s13167-024-00381-5. eCollection 2024 Dec.
4
Exploring body weight-influencing gut microbiota by elucidating the association with diet and host gene expression.通过阐明与饮食和宿主基因表达的关联来探索影响体重的肠道微生物群。
Sci Rep. 2023 Apr 5;13(1):5593. doi: 10.1038/s41598-023-32411-z.
5
The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure.血管性血友病因子抗原与ADAMTS13活性比值：作为慢加急性肝衰竭预后生物标志物的效用
Biology (Basel). 2023 Jan 20;12(2):164. doi: 10.3390/biology12020164.
6
Precision Nutrition in NAFLD: Effects of a High-Fiber Intervention on the Serum Metabolome of NAFD Patients-A Pilot Study.非酒精性脂肪性肝病的精准营养：高纤维干预对非酒精性脂肪性肝病患者血清代谢组的影响——一项初步研究。
Nutrients. 2022 Dec 16;14(24):5355. doi: 10.3390/nu14245355.
7
ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability.ADAMTS13、血管性血友病因子（VWF）和内毒素相互关联，并通过高凝状态与肝硬化的严重程度相关。
J Clin Med. 2022 Mar 26;11(7):1835. doi: 10.3390/jcm11071835.
本文引用的文献
1
Determinants of Outcomes in Autoimmune Hepatitis Presenting as Acute on Chronic Liver Failure Without Extrahepatic Organ Dysfunction upon Treatment With Steroids.自身免疫性肝炎表现为慢性肝衰竭急性发作且在使用类固醇治疗时无肝外器官功能障碍的预后决定因素
J Clin Exp Hepatol. 2021 Mar-Apr;11(2):171-180. doi: 10.1016/j.jceh.2020.08.007. Epub 2020 Aug 22.
2
Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis.通过定量宏基因组学评估肝硬化患者肠道微生物群的改变：与慢加急性肝衰竭及预后的关系
Gastroenterology. 2021 Jan;160(1):206-218.e13. doi: 10.1053/j.gastro.2020.08.054. Epub 2020 Sep 14.
3
A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder.一项关于酒精使用障碍粪便微生物群移植的随机临床试验。
Hepatology. 2021 May;73(5):1688-1700. doi: 10.1002/hep.31496. Epub 2021 Mar 16.
4
Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis.血清代谢产物水平与脂类部分与肝硬化慢加急性肝衰竭和死亡独立相关。
Gastroenterology. 2020 Nov;159(5):1715-1730.e12. doi: 10.1053/j.gastro.2020.07.019. Epub 2020 Jul 17.
5
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.PREDICT研究揭示了急性失代偿性肝硬化的三种具有不同病理生理学特征的临床病程。
J Hepatol. 2020 Oct;73(4):842-854. doi: 10.1016/j.jhep.2020.06.013. Epub 2020 Jul 13.
6
Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans.肠通透性、微生物易位、十二指肠和粪便微生物群的变化及其与人类酒精性肝病进展的关系。
Gut Microbes. 2020 Nov 9;12(1):1782157. doi: 10.1080/19490976.2020.1782157. Epub 2020 Jun 26.
7
Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity.粪便微生物组可区分酒精摄入与酒精性肝炎，但无法区分疾病严重程度。
Hepatology. 2020 Jul;72(1):271-286. doi: 10.1002/hep.31178.
8
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease.酒精使用障碍和酒精相关性肝病患者的肠道微生物群组成及功能特征
Liver Int. 2020 Apr;40(4):878-888. doi: 10.1111/liv.14383. Epub 2020 Feb 3.
9
Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF.血液代谢组学揭示炎症相关的线粒体功能障碍是慢加急性肝衰竭潜在的发病机制。
J Hepatol. 2020 Apr;72(4):688-701. doi: 10.1016/j.jhep.2019.11.009. Epub 2019 Nov 25.
10
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease.噬菌体靶向肠道细菌可减轻酒精性肝病。
Nature. 2019 Nov;575(7783):505-511. doi: 10.1038/s41586-019-1742-x. Epub 2019 Nov 13.
Zotero 插件